Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting

GlobeNewswire June 29, 2017

ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

GlobeNewswire June 7, 2017

ObsEva SA to Attend Jefferies Healthcare Conference in NYC

GlobeNewswire May 31, 2017

ObsEva Reports First Quarter 2017 Financial Results and Business Update

GlobeNewswire May 18, 2017

ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

GlobeNewswire May 18, 2017

ObsEva SA to Attend BioEquity Europe 2017 in Paris

GlobeNewswire May 16, 2017

ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017

GlobeNewswire May 11, 2017

ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids

GlobeNewswire April 25, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  April 13, 2017

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

GlobeNewswire March 24, 2017

ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

GlobeNewswire March 17, 2017

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

GlobeNewswire March 7, 2017

ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC

GlobeNewswire February 3, 2017

Nasdaq Welcomes ObsEva SA (Nasdaq: OBSV) to The Nasdaq Stock Market

GlobeNewswire January 26, 2017

ObsEva SA (Nasdaq: OBSV) to Ring The Nasdaq Stock Market Opening Bell in Celebration of its IPO

GlobeNewswire January 26, 2017

ObsEva SA Announces Pricing of Initial Public Offering

GlobeNewswire January 25, 2017